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Edited by Richard MaraisAbstract Heme oxygenase-1 (HO-1) is a stress response pro-
tein that protects cells against diverse noxious stimuli. Although
regulation of HO-1 occurs mainly at the transcriptional level, its
posttranslational modiﬁcations remain unexplored. We have
identiﬁed a putative consensus sequence for phosphorylation by
Akt/PKB of HO-1 at Ser188. Recombinant human and rat
HO-1, but not mutant HO-1(S188A), are phosphorylated in vi-
tro by Akt/PKB. Isotopic 32P-labeling of HEK293T cells con-
ﬁrmed that HO-1 is a phosphoprotein and that the basal HO-1
phosphorylation is increased by Akt1 activation. HO-
1(S188D), a single point mutant equivalent to the phosphoryl-
ated protein, exhibited over 1.6-fold higher activity than wild
type HO-1. Fluorescence resonance energy transfer (FRET)
studies indicated that HO-1(S188D) bound to cytochrome
P450 reductase (CPR) and biliverdin reductase (BVR) with a
slightly lower Kd than wild-type HO-1. Although the changes
in activity are small, this study provides the ﬁrst evidence for a
role of the survival kinase Akt in the regulation of HO-1.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The serine/threonine protein kinase Akt/PKB exerts a vari-
ety of cell functions that include regulation of glucose metab-
olism and cytoprotection against stress factors, such as oxidant
injury [1]. The mechanisms used by this kinase to prevent oxi-
dant-induced cell death remain poorly deﬁned but probably in-
volve transcription-dependent and -independent mechanisms
[2]. We have recently reported the transcriptional regulation
of heme oxygenase-1 (HO-1) by the PI3K/Akt pathway in re-
sponse to nerve growth factor and to the antioxidant polyphe-
nol, carnosol [3,4].Abbreviations: HO; heme oxygenase; CRP; cytochrome P450 reduc-
tase; BVR; biliverdin reductase; NOS; nitric oxide synthase; CPM;
7-Diethylamino-3-(4-maleimidylphenyl)-4-methylcoumarin; PDGF;
platelet-derived growth factor; FRET; ﬂuorescence resonance energy
transfer
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doi:10.1016/j.febslet.2004.10.077The heme oxygenase family is composed of at least two
well-characterized isoenzymes: inducible HO-1 and constitu-
tive HO-2 [5]. Both isoforms catalyze a common step-wise
degradation of heme to release free iron and equimolar con-
centrations of carbon monoxide (CO) and the linear tetrapyr-
role biliverdin, which in turn is converted to bilirubin by the
enzyme biliverdin reductase (BVR). HO-1 is highly expressed
in reticuloendothelial cells of the spleen and liver, where it
participates in the processing of senescent or damaged eryth-
rocytes and in protection against oxidative damage caused by
free porphyrins [6]. In addition, stimuli that produce oxida-
tive stress (UV light, heavy metals, glutathione depletion,
and H2O2) dramatically enhance HO-1 expression in practi-
cally all tissues and cells tested [7]. Due to the potent antioxi-
dant activity of biliverdin and bilirubin and to the
cytoprotective actions of CO on vascular endothelium and
nerve cells, it is widely accepted that activation of HO-1 rep-
resents an adaptive, and ultimately protective, response to
oxidative injury [8].
The nitric oxide synthase (NOS) and HO systems share sev-
eral functions, including the release of gaseous molecules, NO
or CO, which activate cGMP cyclase, and may act as neuro-
transmitters [9]. Moreover, both systems utilize NADPH as
the electron donor, both exhibit inducible and constitutive iso-
enzymes, and both exert cytoprotective functions in neurons
and other tissues [10]. The NO synthase and HO families are
comprised of isoenzymes that are subject to transcriptional
regulation and phosphorylation. Thus, endothelial NOS is
phosphorylated and activated by Akt/PKB [11,12] and
calcium-calmodulin [13], while HO-2 but not HO-1 is phos-
phorylated and activated by caseine kinase 2 (CK2) [14] and
calcium-calmodulin [15]. Therefore, in this study we analyzed
the possibility that HO-1 could be regulated by Akt-mediated
phosphorylation. Our results identify HO-1 as a new substrate
of Akt and provide an additional mechanism for Akt-mediated
cytoprotection.2. Materials and methods
2.1. Cell culture and transfections
Human embryonic kidney (HEK) 293T and mouse NIH3T3 cells
were grown in Dulbeccos modiﬁed Eagles medium supplemented with
10% fetal bovine serum and 80 lg/ml gentamycin. Transient transfec-
tion of HEK293T was performed with calcium phosphate, yielding up
to 95% transfected cells.ation of European Biochemical Societies.
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proteins
Expression vectors for HA-Akt1, myr-Akt1-HA, HA-Akt1(K179M)
and platelet-derived growth factor (PDGF) beta-receptor have been re-
ported previously [16]. The human HO-1 cDNA was ampliﬁed by PCR
from pCEP-HO-1 (kindly provided by Dr. R. Petersen, Case Western
Reserve University, Cleveland, Ohio) and subcloned into the HindIII/
EcoRI sites of the pFlagCMV2 expression vector to generate an N-ter-
minal, Flag-tagged HO-1 protein. The mutants HO-1(S188A) and
HO-1(S188D) were generated by PCR-directed mutagenesis (details
available upon request) and conﬁrmed by sequence analysis. These
eukaryotic expression vectors were used as templates to amplify trun-
cated forms of HO-1 lacking the last 23 C-terminal amino acids. This
deletion generates a soluble and catalytically active protein [17]. The
ampliﬁed fragments were subcloned into the XhoI/BamHI sites of
pET15b with an amino-terminal tag of 6 His. The truncated proteins
were expressed in BL-21 bacteria and isolated using the ProBonde
puriﬁcation system (Invitrogen, Carlsbad, CA) according to the man-
ufacturers instructions. For ﬂuorescence resonance energy transfer
(FRET) and HO-1 activity assays, proteins were puriﬁed and reconsti-
tuted with hemin as described before [18].
2.3. Immunoblotting
The antibodies used were: anti-HO-1 and anti-Akt from BD-Trans-
duction Lab (Lexington, KY) and Stressgen (Victoria, BC, Canada),
anti-HA from Roche (Indianapolis, IN), anti-phosphoAkt(T308) from
New England Biolabs (Beverly, MA), anti-Flag from Sigma–Aldrich
Corp. (St. Louis, MO) and anti-phospho-Ser from Zymed Laborato-
ries (San Francisco, CA). Cells were washed once with cold phos-
phate-buﬀered saline and lysed on ice with 200 ll of lysis buﬀer (1%
Nonidet P-40, 10% glycerol, 137 mM NaCl, 20 mM Tris–HCl, pH
7.5, 1 lg/ml leupeptin, 1 mM phenylmethylsulfonyl ﬂuoride, 20 mM
NaF, 1 mM sodium pyrophosphate, and 1 mMNa3VO4). Lysates were
precleared by centrifugation, resolved by SDS–PAGE, and transferred
to Immobilon-P membranes (Millipore Billerica, MA). Blots were
analyzed with the appropriate primary antibodies (1:1000). Peroxi-
dase-conjugated secondary antibodies (1:10000) were used to detect
the proteins of interest by enhanced chemiluminescence.
2.4. In vitro kinase assays
In vitro HO-1 phosphorylation was performed in immunocomplexes
with HA-tagged Akt1 that was immunoprecipitated with anti-HA spe-
ciﬁc antibodies from NIH3T3 cells stably transfected with pcDNA3-
HA-Akt1 [16]. Substrates of the kinase reactions included 2 lg of rat
recombinant HO-1 (Calbiochem, La Jolla, CA), histone 2B (Roche)
or human, recombinant, His-tagged, HO-1, HO-1(S188A) and BAD
(from pET30b-BAD, kindly provided by Dr. L. del Peso, Universidad
Auto´noma of Madrid, Madrid) in 20 ll of kinase buﬀer (20 lMATP, 1
mM DTT 1–6 lCi [c-32P]-ATP). Kinase assays with recombinant Akt
were performed using 100 ng of bacterially expressed Akt1 (Upstate
Biotechnology, Lake Placid, NY) per reaction according to the manu-
facturers instructions. Brieﬂy, 2 lg of substrate was incubated with the
kinase and 5 lCi [c-32P]ATP in 25 ll of reaction buﬀer (30 mMMgCl2,
200 lM ATP in 8 mM MOPS, pH 7.2, 2 mM EGTA, 0.4 sodium
orthovanadate and 0.4 mM dithiothreitol) for 40 min at 30 C with
continuous shaking. Kinase reactions were resolved in SDS/PAGE,
blotted to Immobilon-P membranes (Millipore) and exposed to auto-
radiography or immunoblotted.
2.5. Isotopic [32P]-orthophosphate labeling and phosphoamino acid
analyses
HEK293T cells were transiently transfected with pFlag-HO1 or
pFlag-HO1(S188A) constructs. After 16 h, cells were serum-starved
for 16 h, washed three times and incubated for 1 h in phosphate-
and serum-free medium. Metabolic labeling was performed with 1
mCi/ml [32P]-orthophosphate at 37 C for 3 h. Cells were then stim-
ulated with 20 ng/ml PDGF for 10 min. Ectopically expressed HO-1
was immunoprecipitated with anti-Flag antibodies, resolved by SDS–
PAGE and analyzed by autoradiography. Phosphoamino acid anal-
ysis was carried out using two-dimensional thin layer electrophoresis
[19]. Brieﬂy, the band corresponding to labeled Flag-HO-1 was ex-
cised and incubated in 100 ll of 6 N HCl at 110 C for 1 h for acid
hydrolysis. The samples were lyophilized and the resultant pellets
were resuspended in H2O containing phosphoamino acid standardsand applied on a cellulose-coated glass plate. First dimension elect-
rophoresis was done in 1D running buﬀer (2.2% formic acid, 7.8%
glacial acetic acid, pH 1.9) for 1.3 h at 1.5 kV. Second dimension
was done in 2D running buﬀer (5% glacial acetic acid, 0.5% pyridine,
pH 3.5) for 1 h at 1 KV. The plates were air-dried and sprayed with
a ninhydrin solution (0.3 g ninhydrin in 100 ml acetone and 1 ml
acetic acid) to visualize standard amino acids. Phosphoamino acids
were detected by autoradiography.
2.6. Fluorescence resonance energy transfer assays
The binding aﬃnities of human HO-1 and HO-1(S188D) to BVR
and to cytochrome P450 reductase (CPR) were analyzed by FRET,
according to the methods of Wang and Montellano [20]. Rat BVR
and human CPR were expressed, labeled with the ﬂuorescent probe
7-diethylamino-3-(4-maleimidylphenyl)-4-methylcoumarin (CPM)
(Molecular Probes, Eugene, OR) and puriﬁed as previously described
[20]. The UV–Vis spectrum of HO-1 overlaps with the ﬂuorescence
emission of CPM and the association between HO-1 and either
CPM-BVR or CPM-CPR results in ﬂuorescence quenching. The opti-
mal excitation wavelength for CPM in these assays was determined to
be 350 nm. The percentage of ﬂuorescence quenching at 455 nm was
monitored in a SPECTRAmaxTM GEMINIX spectroﬂuorimeter
and referred to the HO-1 concentration (ranging from 12.5 to 800
nM) to calculate Kd values. The binding assay was performed in the
presence of a constant concentration of BVR or CPR (0.05 lM) in
0.1 M potassium-phosphate buﬀer, pH 7.4, at 25 C.
2.7. HO-1 activity
The activities of wild-type HO-1 and the HO-1(S188D) mutant
were determined as the rate of bilirubin formation in an HO-1/
BVR coupled assay [17]. Brieﬂy, the 100 ll reaction mixture con-
tained human cytochrome P450 reductase (0.4 lM), rat BVR (4
lM), hemin (30 lM) and the appropriate recombinant HO-1 protein
(1 lM) in 0.1 M potassium-phosphate buﬀer, pH 7.4. The reaction
was initiated by NADPH (500 lM) addition. The initial rate of
bilirubin formation was monitored at 468 nm for 0–90 s by UV–
Vis spectroscopy at 25 C. Bilirubin concentration was determined
using an e468 of bilirubin of 43.5 mM1 cm1. For determination
of HO activity in HEK293T, cells were lysed in 0.1 M potassium-
phosphate buﬀer, pH 7.4, containing 0.5% Nonidet P40. HO activity
was determined as described above except that 2 mg/ml total pre-
cleared lysate was used as an enzyme source and the rate of bilirubin
formation was monitored for 15 min.3. Results
HO-1 contains two sites that conform to the consensus se-
quence for Akt phosphorylation (RXRXXS/T, where X is
any residue). As shown in Fig. 1, one of these sites (residues
233–246) is found in all vertebrates except humans, who have
N instead of S or T, and was not analyzed further. The other
site (179–193) is present from ﬁsh to humans with conservative
changes to either S or T. Moreover, all HO-2 isoenzymes have
a non-phosphorylatable A, instead of S or T, within this con-
served sequence. According to the algorithm developed by
Yaﬀe et al. [21] (online tool at http://scansite.mit.edu), this se-
quence is likely to be phosphorylated by Akt in vivo, because it
has a score (0.2891) similar to that of other Akt substrates such
as eNOS (0.2032). Moreover, the crystal structure of HO-1 [22]
further indicates that this S is exposed on the surface of this
enzyme, therefore being accessible to Akt.
Consequently, we analyzed the phosphorylation of recomb-
inant HO-1 by Akt in in vitro kinase assays. As a source of ac-
tive Akt, NIH3T3 cells, stably transfected with HA-tagged
Akt1, were serum-starved overnight, stimulated with PDGF
for 10 min, lysed and submitted to immunoprecipitation with
anti-HA antibodies. Immunocomplex kinase assays were per-
formed using commercially available recombinant rat HO-1
Fig. 1. Amino acid alignment of HO-1 and HO-2 sequences around residues 179–193 and 233–246. Asterisks indicate the positions of the two
arginines required to conform to the Akt phosphorylation site. The boxed residues correspond to the putative site of phosphorylation.
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histone 2B. As shown in Fig. 2A, HO-1 was phosphorylated in
immunocomplexes from cells with PDGF-induced activation
of HA-Akt1. The extent of phosphorylation was similar to that
of BAD, a well-established substrate of Akt.
To further determine the role of S188 in Akt-mediated phos-
phorylation of human HO-1, we performed additional in vitro
kinase assays using a wild-type version or a single point S188A
mutant of recombinant His-tagged HO-1 as substrates. As
shown in Fig. 2B, the wild-type enzyme but not the S188A mu-
tant was phosphorylated by active myristoylated myr-Akt1-
HA. In additional experiments, to exclude the possibility that
it is a contaminating kinase present in the immunocomplex,
rather than Akt itself, which is responsible for HO-1 phos-
phorylation, we performed these kinase reactions with bacteri-
ally expressed, puriﬁed Akt1. As shown in Fig. 2C,
recombinant Akt1 phosphorylated wild type HO-1 but not
the HO-1(S188A) mutant. These results indicate that Akt
phosphorylates human HO-1 in vitro at residue S188.
Then, we analyzed the phosphorylation of HO-1 by Akt in
vivo. HEK293T cells were co-transfected with expression vec-
tors for PDGF-beta-receptor, HA-Akt1 and either Flag-HO-
1(wild-type) or mutant Flag-HO-1(S188A). Cells were then
serum-starved for 16 h, isotopically labeled with [32P]-ortho-
phosphate for 3 h, and ﬁnally stimulated with 20 ng/ml of
PDGF for 10 min. Cell lysates were immunoprecipitated with
anti-Flag antibodies, resolved by SDS–PAGE, transferred to
Immobilon-P membranes, and exposed to autoradiography.
The same membrane was also immunoblotted with anti-Flag
antibodies. As shown in Fig. 3A, both HO-1(wild-type) and
HO-1(S188A) exhibited a basal level of phosphorylation in
non-stimulated cells, consistent with the notion that HO-1 is
constitutively phosphorylated in a residue other than S188
[23]. Interestingly, PDGF increased 32P-incorporation into
both proteins but the phosphorylation of the wild-type enzyme
was twofold higher than that of the S188A mutant. Moreover,
as shown in Fig. 3B, phosphoamino acid analysis of both pro-
teins further indicated that basal and induced phosphorylation
takes place on serine residues. These results indicate that HO-1
is basally phosphorylated and that growth factor stimulation
increases the phosphorylation of serine residues, including
the Akt sensitive S188. To further determine if the observed
phosphorylation of HO-1 could be attributed at least in part
to the PI3K/Akt pathway, we analyzed the eﬀect of the PI3Kinhibitor, LY294002. NIH3T3 cells were serum-starved for
16 h and then submitted to 40 lM LY294002 or an equivalent
amount of vehicle (DMSO) for 30 min. Under these condi-
tions, LY294002 completely inhibited PI3K activity in our sys-
tems (data not shown and 4). Then, cells were stimulated with
20 ng/ml PDGF for 10 min. Endogenous HO-1 was immuno-
precipitated with anti-HO-1 antibodies and immunoblotted
with anti-phospho-Ser antibodies. As shown in Fig. 3C, we ob-
served again a low level of HO-1 phosphorylation in non-stim-
ulated cells, regardless of the presence of the PI3K inhibitor,
suggesting that the basal phosphorylation of this protein is
produced by an unknown serine protein kinase that is not re-
lated to PI3K signaling. On the other hand, PDGF induced an
increase in phospho-HO-1 that was partially reduced in the
presence of LY294002. Taken together, these results suggest
that PDGF-induced phosphorylation of HO-1 involves, at
least in part, the PI3K/Akt pathway.
To determine the relevance of phosphorylation in the regu-
lation of HO-1, we attempted to analyze the activity of in vitro
phosphorylated HO-1. However, we could not detect any sig-
niﬁcant production of bilirubin, either in the phosphorylated
enzyme or in the control unphosphorylated enzyme that was
submitted to the same treatment. We speculate that some con-
stituent of the kinase reaction must irreversibly inhibit HO-1
activity. To circumvent this problem, we compared the cata-
lytic activity of wild-type HO-1 with that of the single point
mutant, HO-1(S188D), in which S188 was replaced with an
Asp, a residue that mimics the negative charge introduced by
phosphorylation. Additionally, the sequences coding for the
last 23 C-terminal amino acids were removed to generate sol-
uble but catalytically active recombinant enzymes [16] and a
His-tag was added at the amino-terminus for protein puriﬁca-
tion. Bacterially expressed His-HO-1(wild-type) and His-HO-
1(S188D) were incubated with the substrate heme in the
presence of puriﬁed BVR and CPR, and the production of
bilirubin was monitored at 468 nm. As shown in Table 1, the
single point mutant S188D exhibited a slightly higher activity
(over 1.6-fold) than wild-type HO-1. As an alternative
approach to determine the eﬀect of Akt on HO-1, we analyzed
HO activity in HEK293T cells cotransfected with expression
vectors for Flag-HO-1 and either active Akt (myr-Akt1-HA)
or control inactive Akt (HA-Akt1(K179M)). As shown in
Table 2, lysates from cells expressing active Akt exhibited a
moderate 20% increase in total HO activity.
Fig. 2. Akt phosphorylates HO-1 in vitro. (A) NIH3T3 cells stably
overexpressing HA-Akt were serum-starved for 16 h, stimulated with
20 ng/ml PDGF and used as a source of active kinase. Immunocom-
plex kinase assays were performed with rat recombinant HO-1 and
human recombinant BAD or puriﬁed histone 2B as controls. The
kinase reactions were resolved by SDS–PAGE and transferred to
Immobilon-P membranes. Upper panel, autoradiography showing 32P
incorporation into these substrates. Lower panel, same blot stained
with Ponceau S showing the substrates used in the kinase reaction. (B)
NIH3T3 cells, transfected with vector alone or overexpressing active
myr-Akt1-HA, were used as a negative control and as a source of
active Akt. Immunocomplex kinase assays were performed as in (A),
but using as substrates human, C-terminal truncated, soluble, His-
tagged, HO-1 wild-type or single point mutant S188A. Upper panel,
demonstration of active Akt in the immunocomplexes with activation-
speciﬁc anti-phosphoAkt(T308). Upper middle panel, immunoblot with
anti-HA antibodies showing speciﬁc immunoprecipitation of HA-
tagged, myristoylated Akt. Lower middle panel, the kinase reactions
were resolved in SDS–PAGE, transferred to Immobilon-P membranes
and submitted to autoradiography. Lower panel, same blot stained
with Ponceau S showing the substrates used in the kinase reaction. (C)
Kinase assays were performed with bacterially expressed Akt1. Upper
panel, immunoblot with anti-Akt antibodies showing recombinant Akt
in the kinase reactions. Middle panel, autoradiography showing 32P
incorporation into recombinant HO-1. Lower panel, same blot stained
with Ponceau S showing similar amount of HO-1 protein in each
kinase reaction.
Fig. 3. Akt phosphorylates HO-1 in vivo. (A) HEK293T cells were
cotransfected with expression vectors for the PDGF beta-receptor,
HA-tagged Akt and either Flag-tagged wild-type HO-1 or Flag-tagged
HO-1(S188A) single point mutant. Then, cells were treated as detailed
in Methods and stimulated with 20 ng/ml PDGF for 10 min as
indicated. Upper panel, cell lysates were immunoprecipitated with anti-
Flag antibodies, resolved by SDS–PAGE, transferred to Immobilon P-
membrane and exposed to autoradiography. Lower panel, immunoblot
of the same blot with anti-Flag antibodies showing similar load of
Flag-HO1 per lane. (B) Phosphoamino acid analysis of wild type and
S188A Flag-HO-1 from the corresponding PDGF-stimulated bands in
(A). Punctuated areas indicate the positions of phosphoamino acid
standards as determined by ninhydrin staining. (C) HO-1 phosphory-
lation is partially blocked by the PI3K inhibitor, LY294002. Serum-
starved NIH3T3 cells were preincubated with vehicle or 40 lM
LY294002 for 30 min and then stimulated with 20 ng/ml PDGF for 10
min. Endogenous HO-1 was immunoprecipitated with anti-HO-1
speciﬁc antibodies, resolved in PAGE/SDS, and immunoblotted with
anti-phospho-Ser antibodies. Upper panel, detection of phospho-Ser in
the HO-1 immunocomplexes. Lower panel, immunoblot of the same
blot with anti-HO-1 antibodies showing even amount of immunopre-
cipitated HO-1 per lane.
Table 1
Activity of His-tagged HO-1 proteins determined as the rate of
bilirubin formation in the presence of BVR and CPR
Enzyme BR formation rate




His-HO-1(wild-type) 0.273 ± 0.057 7 100
His-HO-1(S188D) 0.481 ± 0.086 9 176
Experiment 2
His-HO-1(wild-type) 0.208 ± 0.045 9 100
His-HO-1(S188D) 0.336 ± 0.077 9 161
N indicates number of samples per experiment.
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rily on electrostatic charge pairing on a surface binding site
that includes residues close to S188 [20]. Therefore, phosphory-lation of this residue might change the aﬃnity among these
molecules. For that reason, we determined the dissociation
constants of CPR and BVR by FRET using recombinant
His-HO-1(wild-type) and His-HO-1(S188D) and CPM-labeled
BVR or CPR, as reported previously for other HO-1 point mu-
tants [20]. As shown in Table 3, the mutant His-HO-1(S188D)
Table 2
Measurement of HO activity in HEK293T cells transfected with
expression vectors for Flag-HO-1 and active (myr-Akt1-HA) or
inactive (HA-Akt1(K179A)) versions of Akt protein kinase
Enzyme BR formation rate




Flag-HO-1 + HA-Akt1(K179M) 102.57 ± 5.78 100
Flag-HO-1 + myr-Akt1-HA 122.72 ± 11.38 119.64
Experiment 2
Flag-HO-1 + HA-Akt1(K179M) 94.58 ± 10.86 100
Flag-HO-1 + myr-Akt1-HA 112.63 ± 2.3 119.07
Even amounts of Flag-HO-1 for each experimental condition were
conﬁrmed in aliquots resolved by SDS–PAGE and stained with Coo-
massie blue (data not shown). HO activity was determined in cell ly-
sates as the rate of bilirubin formation in the presence of BVR and
CPR.
a Each value is the average of three samples. The basal rate of HO
activity, corresponding to control cells transfected with empty vectors,
was 6.89 ± 0 and 4.59 + 0.5 for experiments 1 and 2, respectively.
Table 3
Binding of CPR and BVR to HO-1 by FRET
Enzyme Kd CPR (nM)
a Kd relative to
wild type HO-1
His-HO-1(wild-type) 179.5 ± 45.5
His-HO-1(S188D) 139.5 ± 50.36 0.77
Enzyme Kd BVR (nM)
a Kd relative to
wild type HO-1
His-HO-1(wild-type) 14.8 ± 9.195
His-HO-1(S188D) 9.88 ± 5.365 0.66
a Each value is the average of two independent experiments with three
samples each. The S.D. of each experiment was less than 30%. The
indicated range ± is half of the diﬀerence between the two independent
experiments.
94 M. Salinas et al. / FEBS Letters 578 (2004) 90–94exhibited a slightly reduced Kd for both BVR and CPR. There-
fore, the negative charge introduced by phosphorylation of
S188, which is mimicked by the S188D mutant, modestly in-
creases the aﬃnity of HO-1 for these molecular partners.4. Discussion
HO-1, initially identiﬁed as Hsp32, appears to be involved in
oxidative stress protection. The well-characterized transcrip-
tional induction of this enzyme might provide long-term oxi-
dant protection, but as in the case of NOS and HO-2,
immediate protection might depend on fast activation of the
pre-existing basal HO-1 levels [14,15]. Since Akt/PKB is rap-
idly activated in response to strong oxidants such as hydrogen
peroxide [24], we reasoned that, similarly to NOS, HO-1 activ-
ity might be regulated through Akt-mediated phosphorylation.
In this study, we have conﬁrmed that HO-1 is phosphorylated
by Akt in vitro and in vivo. Moreover, we have observed a
moderate increase in in vitro HO-1 activity and in binding
aﬃnity for BVR and CPR and in the HO activity of cells
expressing active Akt.
Ser 188 lies on the surface involved in electrostatic interac-
tions between HO-1 and its well-characterized partners, BVR
and CPR. Some ionic surface residues involved in these inter-
actions include Lys18, Lys22, Lys179, Arg183, Arg198, Glu19,
Glu127, and Glu190 for CPR and Lys18, Lys22, Lys179,Arg183, and Arg185 for BVR [20]. Therefore, S188 lies very
close to this interface and phosphorylation may change the
strength of binding. However, considering the large number
of residues involved in the interaction, a large change in bind-
ing aﬃnity is not to be expected for a single phosphorylation
event. Indeed, we report that the change of Ser for Asp, a res-
idue that mimics the negative charge of phosphorylation, re-
sults in a slightly lower Kd for both CPR and BVR and a
slightly increased HO-1 activity.
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